GP-2250

Geistlich Pharma AG · Phase 1 active Small molecule

At a glance

Generic name	GP-2250
Also known as	gemcitabine
Sponsor	Geistlich Pharma AG
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GP-2250 CI brief — competitive landscape report
GP-2250 updates RSS · CI watch RSS
Geistlich Pharma AG portfolio CI